Avalon selects new clinical development candidate for cancer treatment
This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The company plans to begin clinical testing of AVN316 in patients in
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).